Weekly Analysts’ Ratings Changes for CG Oncology (CGON)

A number of research firms have changed their ratings and price targets for CG Oncology (NASDAQ: CGON):

• 8/8/2026 – CG Oncology was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/7/2026 – CG Oncology had its price target lowered by Royal Bank Of Canada from $81.00 to $79.00. They now have an “outperform” rating on the stock.
• 8/7/2026 – CG Oncology had its price target raised by Piper Sandler from $82.00 to $85.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – CG Oncology had its price target raised by Truist Financial Corporation from $82.00 to $85.00. They now have a “buy” rating on the stock.
• 7/29/2026 – CG Oncology had its “buy” rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.
• 7/17/2026 – CG Oncology had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other CG Oncology news, Director James Mulay sold 24,165 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the transaction, the director owned 24,165 shares of the company’s stock, valued at approximately $1,816,241.40. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Leonard E. Post sold 5,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total value of $350,000.00. Following the transaction, the director directly owned 5,000 shares in the company, valued at approximately $350,000. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 38,129 shares of company stock worth $2,738,357 in the last quarter. Insiders own 4.80% of the company’s stock.

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.